Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115684 | 0.85 | ALDH1A1 (0.50) | ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL4190993 | 0.84 | GRIN2B (0.39) | BCHEMAOBSIGMAR1ALDH1A1MEN1 | |
| SCHEMBL4193805 | 0.83 | GRIN2B (0.38) | BCHEMAOBSIGMAR1ALDH1A1MEN1 | |
| SCHEMBL4161374 | 0.82 | CHRM4 (0.44) | ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL1697177 | 0.82 | CHRM4 (0.44) | ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL5385059 | 0.81 | CHRM4 (0.43) | ALDH1A1L3MBTL1 | |
| SCHEMBL4179654 | 0.78 | BCHE (0.38) | BCHEMAOBSIGMAR1MEN1KMT2A | |
| SCHEMBL3217075 | 0.78 | BCHE (0.37) | BCHEMAOBSIGMAR1ACHES1PR5 | |
| SCHEMBL3205175 | 0.78 | BCHE (0.37) | BCHEMAOBSIGMAR1ACHES1PR5 | |
| SCHEMBL4180019 | 0.78 | POLB (0.33) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194862-A1 | 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-31 | — | — | US | claimed |
| US-7465751-B2 | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-16 | — | — | US | disclosed |
| US-20060194862-A1 | 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194862-A1 | 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | CHRM3, CHRM1, CHRM5 | BCHE 763/4885MAOB 611/4885SIGMAR1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.